Cancer centre sues BMS and Ono over alleged patent exploitation

25-06-2019

Cancer centre sues BMS and Ono over alleged patent exploitation

Katherine Welles / Shutterstock.com

Boston-based Dana-Farber Cancer Institute is seeking a share of the $1.6 billion in licensing revenue that BMS and Ono Pharmaceutical Co have allegedly received from six immunotherapy patents.


BMS, Ono Pharmaceutical Co, Dana-Farber Cancer Institute, patent ownership, inventorship, licensing revenues

LSIPR